Closed door meeting on Capitol Hill looks to set the agenda for patent legislation in next Congress
Days after announced trade truce, China’s government explains ‘social credit score’ consequences for IP infringers first floated three years ago. Penalties range from borrowing restrictions to air travel bans.
First application of the court’s SimpleAir standard led to a 45% slump in Invidior’s share price and could prove to be a boon for generics companies
Shanghai Xuanpu appears to have risen from ashes of a state-backed semiconductor venture. Recent validity decisions mean its activities should be monitored by anyone implementing the TD-SCDMA standard in China
The landmark judgment makes it harder for pharmaceutical companies to use what has become an important source of protection – so opening the way for more generic competition
In overturning a lower court decision to invalidate, the court has provided some welcome relief to those holding rights in the field - but for applicants there remains a great deal of uncertainty
A pair of recent decisions from the Federal Court of Australia suggest that it may be about to become more difficult for drug patent owners to prevail in requests for interlocutory injunctions.
How to ensure that the use of open source packages does not run contrary to corporate IP policies.
Shift to Phillips claim construction standard brings Board in line with district courts and could make it harder to invalidate patents in a venue that many rights owners have come to dread
Johns Hopkins and the University of Wisconsin both had research collaborations come under the microscope for IP reasons last week.
Former deputy general counsel of A10 Networks appointed to serve as Director Iancu’s number two and seems to share her boss’s opinion on one of the patent reform movement’s hobby horses
Last week the DOJ charged Jinhua and UMC with stealing Micron trade secrets. China sees an effort to cut off its tech progress, US sees a pattern of disrespect for IP and Taiwan is caught in the crossfire.
Court of Justice delivers decision that will make it harder for inventors of device-drug combination products to obtain patent term extensions
With biopharma businesses facing up to unprecedented technological change, the IP issues that they deal with may begin to look more like those that have already become common elsewhere
Beijing-based panel maker that’s one of China’s fastest-growing patent filers is latest target of the deepening partnership between IV and the Texas-based NPE